

UNIVERSITI PUTRA MALAYSIA AGRICULTURE • INNOVATION • LIFE

Abnormalities of Platelet

Morphology Workshop for Medical Laboratory
Technologist
22 February 2018

About platelet...& your personal experience...



PLATELET ALERTS..



AGRICULTURE . INNOVATION . LIFE




Learning outcomes



- Detect and identify various morphologic abnormalities of platelets.
- Relate abnormal blood smear findings to specific clinical diagnoses.
- Interpret abnormal smear findings in the context of arriving at a diagnosis with or without recommendation for additional workup.









Morphologic abnormalities




- Large and giant platelet- cause of pseudothrombocytopenia
- Megakaryocyte fragments-occasionally seen in myeloproliferative neoplasm (MPNs)
- Anisocytosis- may be seen in MPN


Causes of pseudothrombocytopenia



AGRICULTURE • INNOVATION • LIFE

- Platelet clumping
- Large and giant platelets
- Platelet satellitism






Thrombocytopenia



- Occurs across age: neonatal to elderly
- Various causes
- Clinical history is mandatory
- Common in our setting : drugs, infection ie dengue, primary immune thrombocytopenia





Pseudothrombocytopenia

Disorders of decreased platelet production

- Certain viral infections
- Myelosuppressive therapy (e.g. chemotherapy, radiation)
- Congenital thrombocytopenias
- Ethanol toxicity
- Folate or vitamin B12 deficiency
- Bone marrow disorders (e.g. MDS, myelofibrosis, leukemia, other malignancies involving the marrow)

Disorders of decreased platelet survival

- Certain drugs (e.g. heparin, quinine)
- Alloimmune thrombocytopenias (e.g. post-transfusion purpura)
- Disseminated intravascular coagulation
- Thrombotic thrombocytopenic purpura-Hemolytic uremic syndrome
- Cardiopulmonary bypass

Dilutional thrombocytopenia

Splenic sequestration

- Portal hypertension
- Infiltrative diseases of the spleen

Immune thrombocytopenia



AGRICULTURE . INNOVATION . LIFE

	Immune Thrombocytopenia	Neonatal Alloimmune Thrombocytopenia	Posttransfusion Purpura
Immune reaction	Autoimmune	Alloimmune	Features of both allo- and autoimmunity
Incidence	Five per 100,000 population	40 per 100,000 births (or one per 2,500)	One per 100,000 blood transfusions
Principal antigenic target	GPIIb/IIIa	HPA-1a	HPA-1a plus autoantigens
Nature of the antibody	Intermittent	Persistent (past 1 year)	Persistent often at high titers
Mode of sensitization	Autoantibody	Alloantibody	Features of allo- and autoantibodies
Sensitizing event	Mostly unknown; some viral illnesses, chronic infection	Exposure to fetal platelet antigens early in first pregnancy	Blood transfusion (RBCs or platelets) 5-10 days earlier
Bleeding frequency	Uncommon	Common	Very common
Epidemiology	Higher incidence in children and elderly adults; female predominance in early adulthood	Majority affects fetus or newborn carrying the HPA-1a antigen	Almost all are HPA-1bb women sensitized by previous transfusion or pregnancy

Drug induced thrombocytopenia 😈 📖

AGRI	CULTUR	F • INNOVA	TION . LIFE

Type	Mechanisms	Examples	
Hapten-induced antibody	diventified and acts as a harten to induce a		
Drug-dependent antibody	Drug binds to membrane glycoprotein and forms a compound epitope or induces a conformational change elsewhere in the molecule for which the antibody is specific. The immunogen can be a drug metabolite.	Quinidine, quinine, NSAIDs, various antibiotics, sedatives, anticonvulsants, many others	
GP IIb/IIIa inhibitors (ligand mimetic)	Drug reacts with the RGD recognition sequence on GP IIb/IIIa and induces a conformational change elsewhere in the integrin complex that is recognized by antibody.	Tirofiban, eptifibatide, roxifiban, others	
Drug-specific antibody	Drug (chimeric Fab fragment) induces antibodies specific for murine sequences that control specificity for GP IIb/IIIa.	Abciximab	
Drug-induced autoantibody	Drug perturbs the immune response so that drug-independent antibodies specific for a cell membrane glycoprotein are produced.	Gold salts, procainamide	
Immune complex Drug forms an immunogenic complex with PF4; antibody binds and forms an immune complex; the immune complex activates platelets by way of Fc receptors.		Heparin	

Drug induced antibody



AGRICULTURE . INNOVATION . LIFE

Classification	Mechanism	Specific Drugs	
Autoantibody	Drug induces antibody that reacts with autologous platelets in the absence of the drug	Gold, procainamide	
Drug specific antibody	Antibody recognizes murine component of chimeric Fab fragment specific for platelet membrane glycoprotein IIIa	Abciximab	
Fiban-type drug	Drug reacts with glycoprotein IIb/IIIa to induce a conformational change recognized by antibody	Eptifibatide, tirofiban	
Hapten-dependant	Hapten links covalently to membrane protein and induces drug-specific immune response	Cephalosporins, piperacillin	
Immune complex	Drug binds to platelet factor 4 to produce an antigenic complex against which antibodies react; resulting immune complexes bind to platelet Fc receptors resulting in platelet activation	Heparin and low molecular weight heparin	
Quinine-type	Drug induces antibody that binds to membrane protein in presence of soluble drug	Quinine, quinidine, NSAIDs, sulfonamides	


Inherited thrombocytopenia



AGRICULTURE • INNOVATION • LIF

LARGE

Algorithm for Diagnosis of Familial Thrombocytopenia



Eczema, X-linked WAS

No eczema, X-linked XLT

AR, High TPO CAMT

Radial defects TAR, ATRUS

AD, FHx AML Runx1

11q deletion
Paris Trousseau

AD, minimal bleeding
Cytochrome C
ANKRD26

Flow for GPIb/IX
BSS

AD, WBC inclusions MYH9

VWF multimers, RIPA
Type IIB VWD, TTP
GPlb mutation

Red cells abnl GATA1 ABCG5/8

EM Granula disorder



Approach to thrombocytopenia

THROMBOCYTOPENIA

rule out pseudothrombocytopenia

SEQUESTRATION

↓ PRODUCTION

↑ DESTRUCTION

look for splenomegaly

Causes of splenomegaly

- infection
- inflammation
- congestion
- maligancy
- · red cell disorders
- storage diseases

bone marrow investigation review meds

- aplasia
- infiltration
- ineffective megakaryopoiesis eg. MDS
- selective impairment of platelet production

look for underlying disorders review meds

- immune auto-immune (ITP, SLE drugs
- infections allo-immune
- non-immune sepsis DIC, TTP, HUS hypertensive disorders of pregnancy


Also

Artefactual (false) or pseudothrombocytopenia

-Clot in the sample.- Platelets clumped.

Congenital thrombocytopenia


-Rare inherited disorders (eg May Hegglin Anomaly).



Neonatal thrombocytopenia



AGRICULTURE • INNOVATION • LIF



- Birth asphyxia
- Chronic placental insufficiency
- Congenital infections (TORCH)
- Perinatal infections (E. coli, GBS)
- Neonatal alloimmune thrombocytopenia (NAIT)
- Autoimmune cases (Lupus, ITP)
- Thrombosis
- Kasabach-Merritt syndrome
- Inherited (Congenital amegakaryocytic thrombocytopenia)


- Sepsis
- NEC
- Congenital infections (TORCH)
- Autoimmune
- Kasabach-Merritt syndrome
- Inherited (Congenital amegakaryocytic thrombocytopenia)

Williams hematology, 8e. Chapter 119 Chakravorty et al, Brit Jour of Hematology, 2011

Thrombocytopenia-approach



AGRICULTURE • INNOVATION • LIFE



URGENT ATTENTION NEEDED...



10						A 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	COLIURE - INNOVATION - 1
MAHA + Low Pits	Pathophysiology	Abdominal pain	AKI	ALI	High PT/PTT	Treatment	Unique feature(s)
TTP	Deficiency in ADAMSTS 13 (<10%) (antibodies) vs. hereditary form (Upshaw-Shulman Syndrome)	++	+	+/-	-	Plasma exchange (PEX) Glucocorticoids Rituximab	Recombinant ADAMTS13 and anti-vWF on the horizon Plt transfusions reserved for those with active bleeding
HUS	Shiga toxin (Shigella dysenteriae and EColi O157:H7) with direct epithelial and endovascular damage vs. hereditary form (atypical HUS)	++	++	+/-	-	Supportive care Eculizumab (anticomplement therapy) for hereditary forms for aHUS	Plt transfusions reserved for those with active bleeding
HELLP	? severe pre-eclampsia; no clear understanding of pathophysiology but felt to be systemic inflammatory response	++ (40-90% per UpToDate)	+	(Criteria: TBili >1.2 and AST >2x ULN)	+	Delivery of fetus Supportive care Steroids?	Plt transfusions reserved for those with active bleeding (if c-section, consider Plt 40-50k)
DIC	Abnormal regulation of coagulation and fibrinolysis because of a variety of etiologies	+/-	+ (25-40%)	+ (19%)	*From 1978 case series of 118 pts with acute DIC	Treat the underlying etiology Supportive care Prevention/Treatment of bleeding and thrombosis: ? heparin infusion, fibrinogen (100-150)	Etiologies include but are not limited to: Sepsis, malignancy, trauma, ob complications (preeclampsia, fetal demise, AFLP), intravascular hemolysis, drugs and toxins

Thrombocytosis



- When platelet count is above reference range observed in population concerned
- Various causes implicated
- Common in our setting: response to stress-inflammation, infection, iron deficiency (reactive)



SPURIOUS THROMBOCYTOSIS

Cryoglobulinemia

Cytoplasmic fragmentation in acute leukemia

Red cell fragmentation

Bacteremia

REACTIVE (SECONDARY) THROMBOCYTOSIS

Transient thrombocytosis

Acute blood loss

Recovery from thrombocytopenia (rebound

thrombocytosis)

Acute infection or inflammation

Response to exercise

Response to drugs (vincristine, epinephrine, all-transretinoic acid)

Sustained thrombocytosis

Iron deficiency

Splenectomy or congenital absence of spleen

Malignancy

Chronic infection or inflammation

Hemolytic anemia

FAMILIAL THROMBOCYTOSIS

CLONAL THROMBOCYTOSIS

Essential thrombocythemia

Polycythemia Vera

Primary myelofibrosis

Chronic myeloid leukemia


Refractory anemia with ringed sideroblasts and thrombocytosis

5a minua ayadaama



Approach to thrombocytosis in MPN

AGRICULTURE . INNOVATION . LIFE



Take home message



AGRICULTURE • INNOVATION • LIFE

- Be aware of various causes of platelet abnormalities
- Always check with clinical history and previous results (if available)
- When in doubt/unsure, ask for help.



TERIMA KASIH/THANK YOU

www.upm.edu.my



















